Dual Role of PPAR-γ in Induction and Expression of Behavioral Sensitization to Cannabinoid Receptor Agonist WIN55,212-2

[1]  M. Diana.  The Addicted Brain , 2013, Front. Psychiatry.

[2]  P. Di Ciano,et al.  Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. , 2013, Current drug targets.

[3]  F. Moradi,et al.  WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway , 2012, Neuropharmacology.

[4]  B. Cravatt,et al.  β−Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR‐α, PPAR‐γ and TRPV1, but not CB1 or CB2 receptors , 2012, British journal of pharmacology.

[5]  E. Masini,et al.  The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke. , 2012, Current drug targets.

[6]  J. Wiley,et al.  Locomotor activity changes in female adolescent and adult rats during repeated treatment with a cannabinoid or club drug , 2011, Pharmacological reports : PR.

[7]  Jian Zhang,et al.  Inhibition of COX‐2 expression by endocannabinoid 2‐arachidonoylglycerol is mediated via PPAR‐γ , 2011, British Journal of Pharmacology.

[8]  P. Kalivas,et al.  Drug Wanting: Behavioral Sensitization and Relapse to Drug-Seeking Behavior , 2011, Pharmacological Reviews.

[9]  S. Maier,et al.  Stress- and glucocorticoid-induced priming of neuroinflammatory responses: Potential mechanisms of stress-induced vulnerability to drugs of abuse , 2011, Brain, Behavior, and Immunity.

[10]  M. Heilig,et al.  Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking , 2011, Biological Psychiatry.

[11]  E. Unterwald,et al.  Methanandamide blocks amphetamine-induced behavioral sensitization in rats. , 2010, European journal of pharmacology.

[12]  L. Vanderschuren,et al.  Sensitization processes in drug addiction. , 2010, Current topics in behavioral neurosciences.

[13]  S. Ramiro-Fuentes,et al.  The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine , 2009, Neuroscience.

[14]  G. Wenk,et al.  Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain , 2009, Molecular Psychiatry.

[15]  K. Antoniou,et al.  Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. , 2009, Life sciences.

[16]  M. Koch,et al.  Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment , 2009, Brain Research.

[17]  D. McGehee,et al.  Nicotine and Behavioral Sensitization , 2009, Journal of Molecular Neuroscience.

[18]  M. Pistis,et al.  Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors , 2008, The Journal of Neuroscience.

[19]  M. Reith,et al.  Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. , 2008, CNS & neurological disorders drug targets.

[20]  G. Gerdeman,et al.  Context-Specific Reversal of Cocaine Sensitization by the CB1 Cannabinoid Receptor Antagonist Rimonabant , 2008, Neuropsychopharmacology.

[21]  M. Hows,et al.  The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B , 2008, British journal of pharmacology.

[22]  V. Marzo,et al.  The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus , 2008, Pharmacology Biochemistry and Behavior.

[23]  V. Marzo,et al.  The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization , 2008, Behavioural Brain Research.

[24]  P. Bernante,et al.  The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. , 2007, The Journal of clinical endocrinology and metabolism.

[25]  S. O'Sullivan,et al.  Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.

[26]  Akihiro Yamamoto,et al.  Peroxisome Proliferator-Activated Receptor Gamma Activation Relieves Expression of Behavioral Sensitization to Methamphetamine in Mice , 2007, Neuropsychopharmacology.

[27]  G. Bing,et al.  Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system , 2007, Journal of neurochemistry.

[28]  G. Bing,et al.  Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. , 2007, Current neuropharmacology.

[29]  Stephen P. H. Alexander,et al.  Cannabinoids and PPARα signalling , 2006 .

[30]  G. Landreth,et al.  PPARγ as a therapeutic target in central nervous system diseases , 2006, Neurochemistry International.

[31]  C. Nicol,et al.  Inflammatory modulation of PPARγ expression and activity , 2006 .

[32]  C. Thiemermann,et al.  Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. , 2006, European journal of pharmacology.

[33]  Stephen P. H. Alexander,et al.  Cannabinoids and PPARalpha signalling. , 2006, Biochemical Society transactions.

[34]  C. Nicol,et al.  Inflammatory modulation of PPAR gamma expression and activity. , 2006, Clinical immunology.

[35]  T. Robinson,et al.  Neural and Behavioral Plasticity Associated with the Transition from Controlled to Escalated Cocaine Use , 2005, Biological Psychiatry.

[36]  S. Burstein.  PPAR-γ: A nuclear receptor with affinity for cannabinoids , 2005 .

[37]  M. Koch,et al.  Effects of the cannabinoid receptor agonist win 55,212-2 on operant behavior and locomotor activity in rats , 2005, Pharmacology Biochemistry and Behavior.

[38]  S. Burstein.  PPAR-gamma: a nuclear receptor with affinity for cannabinoids. , 2005, Life sciences.

[39]  S. Mangiavacchi,et al.  Psychomotor stimulants and neuronal plasticity , 2004, Neuropharmacology.

[40]  M. Asanuma,et al.  Specific Gene Expression and Possible Involvement of Inflammation in Methamphetamine‐Induced Neurotoxicity , 2004, Annals of the New York Academy of Sciences.

[41]  T. Hasegawa,et al.  Role of Tumor Necrosis Factor-α in Methamphetamine-Induced Drug Dependence and Neurotoxicity , 2004, The Journal of Neuroscience.

[42]  J. Kauer.  Learning mechanisms in addiction: synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse. , 2004, Annual review of physiology.

[43]  P. Ferré,et al.  The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. , 2004, Diabetes.

[44]  E. Hirsch,et al.  Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease , 2002, Journal of neurochemistry.

[45]  G. Landreth,et al.  Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer’s disease , 2001, Neurobiology of Aging.

[46]  S. Goldberg,et al.  Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys , 2000, Nature Neuroscience.

[47]  K. Berridge,et al.  The psychology and neurobiology of addiction: an incentive-sensitization view. , 2000, Addiction.

[48]  P. Kalivas,et al.  Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies , 2000, Psychopharmacology.

[49]  O. Hurtado,et al.  Implication of Glutamate in the Expression of Inducible Nitric Oxide Synthase After Oxygen and Glucose Deprivation in Rat Forebrain Slices , 2000, Journal of neurochemistry.

[50]  J. Walker,et al.  Activational role of cannabinoids on movement. , 2000, European journal of pharmacology.

[51]  G. Landreth,et al.  Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists , 2000, The Journal of Neuroscience.

[52]  R. Wise,et al.  Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats , 1999, Brain Research.

[53]  A. Imperato,et al.  Cannabinoid penetration into mouse brain as determined by ex vivo binding. , 1999, European Journal of Pharmacology.

[54]  R. Mechoulam,et al.  Biphasic Effects of Anandamide , 1998, Pharmacology Biochemistry and Behavior.

[55]  C. O'brien,et al.  A range of research-based pharmacotherapies for addiction. , 1997, Science.

[56]  G. Di Chiara,et al.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. , 1997, Science.

[57]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[58]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  T. Robinson,et al.  Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.

[60]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .